Publications by authors named "Eric Mayoux"

Claim this Profile
S
SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans.
Heeyoung Chae, Robert Augustin, Eva Gatineau, Eric Mayoux, Mohammed Bensellam

Mol Metab· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition.
Issei Tomita, Shinji Kume, Sho Sugahara, Norihisa Osawa, Kosuke Yamahara, Eric Mayoux

Cell Metab· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Angiotensin II-induced redox-sensitive SGLT1 and 2 expression promotes high glucose-induced endothelial cell senescence.
Sonia Khemais-Benkhiat, Eugenia Belcastro, Noureddine Idris-Khodja, Sin-Hee Park, Lamia Amoura, Eric Mayoux

J Cell Mol Med· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat.
Sin-Hee Park, Muhammad Akmal Farooq, Sébastien Gaertner, Christophe Bruckert, Abdul Wahid Qureshi, Eric Mayoux

Cardiovasc Diabetol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single dose of empagliflozin increases in vivo cardiac energy status in diabetic db/db mice.
Desiree Abdurrachim, Emmy Manders, Klaas Nicolay, Eric Mayoux, Jeanine J Prompers

Cardiovasc Res· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors.
Subodh Verma, Sonia Rawat, Kim L Ho, Cory S Wagg, Liyan Zhang, Eric Mayoux

JACC Basic Transl Sci· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Favorable Effect of Empagliflozin on Erectile Function in an Experimental Model of Type 2 Diabetes.
Rana Assaly, Diane Gorny, Sandrine Compagnie, Eric Mayoux, Jacques Bernabe

J Sex Med· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Organic anion transporter OAT3 enhances the glucosuric effect of the SGLT2 inhibitor empagliflozin.
Yiling Fu, Davorka Breljak, Akira Onishi, Falk Batz, Rohit Patel, Eric Mayoux

Am J Physiol Renal Physiol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
Annayya R Aroor, Nitin A Das, Andrea J Carpenter, Javad Habibi, Guanghong Jia, Eric Mayoux

Cardiovasc Diabetol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats.
Sebastian Steven, Matthias Oelze, Alina Hanf, Swenja Kröller-Schön, Fatemeh Kashani, Eric Mayoux

Redox Biol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice.
Liang Xu, Naoto Nagata, Mayumi Nagashimada, Fen Zhuge, Yinhua Ni, Eric Mayoux

EBioMedicine· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes.
Nadjib Hammoudi, Dongtak Jeong, Rajvir Singh, Ahmed Farhat, Michel Komajda, Eric Mayoux

Cardiovasc Drugs Ther· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes.
Javad Habibi, Annayya R Aroor, James R Sowers, Guanghong Jia, Melvin R Hayden, Eric Mayoux

Cardiovasc Diabetol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Comment on Ferrannini et al. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Diabetes Care 2016;39:1108-1114.
Ele Ferrannini, Michael Mark, Eric Mayoux

Diabetes Care· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Comment on Ferrannini et al. Diabetes Care 2016;39:1108-1114. Comment on Mudaliar et al. Diabetes Care 2016;39:1115-1122.
Ele Ferrannini, Michael Mark, Eric Mayoux

Diabetes Care· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation.
Elisa Benetti, Raffaella Mastrocola, Giovanna Vitarelli, Juan Carlos Cutrin, Debora Nigro, Eric Mayoux

J Pharmacol Exp Ther· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes.
Sam Tsz Wai Cheng, Lihua Chen, Stephen Yu Ting Li, Eric Mayoux, Po Sing Leung

PLoS One· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism.
François Briand, Eric Mayoux, Emmanuel Brousseau, Noémie Burr, Isabelle Urbain

Diabetes· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Ele Ferrannini, Michael Mark, Eric Mayoux

Diabetes Care· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of Micro-RNA Changes during the Progression of Type 2 Diabetes in Zucker Diabetic Fatty Rats.
Denis Delic, Claudia Eisele, Ramona Schmid, Gerd Luippold, Eric Mayoux

Int J Mol Sci· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin.
Matthias Kern, Nora Klöting, Michael Mark, Eric Mayoux, Thomas Klein

Metabolism· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans.
Martin C Michel, Eric Mayoux, Volker Vallon

Naunyn Schmiedebergs Arch Pharmacol· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity.
Matthias Oelze, Swenja Kröller-Schön, Philipp Welschof, Thomas Jansen, Michael Hausding, Eric Mayoux

PLoS One· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat.
Henrik H Hansen, Jacob Jelsing, Carl Frederik Hansen, Gitte Hansen, Niels Vrang, Eric Mayoux

J Pharmacol Exp Ther· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet.
Steven P Vickers, Sharon C Cheetham, Katie R Headland, Keith Dickinson, Rolf Grempler, Eric Mayoux

Diabetes Metab Syndr Obes· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis